SCHEMBL359803

SCHEMBL359803

OC1NCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
DRD1 P21728 6/20 0.42
DRD2 P14416 4/20 0.42
DRD4 P21917 4/20 0.42
MAPK1 P28482 3/20 0.42
CYP2D6 P10635 3/20 0.42
TP53 P04637 2/20 0.42
CYP1A2 P05177 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 1/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29568322 1.00 CHRNB2 (0.44) CHRNB2CHRNA4DRD1DRD2DRD4
SCHEMBL14395237 1.00 CHRNB2 (0.44) CHRNB2CHRNA4DRD1DRD2DRD4
Hydrochloric Acid SCHEMBL27585427 0.98 MAPT (0.44) CHRNB2CHRNA4DRD1DRD2DRD4
Bromide SCHEMBL3966126 0.98 CHRNB2 (0.42) CHRNB2CHRNA4DRD1DRD2DRD4
SCHEMBL358171 0.78 PRCP (0.58) DRD1MAPTTSHR
SCHEMBL30924714 0.78 PRCP (0.58) DRD1MAPTTSHR
SCHEMBL16224765 0.78 PARP1 (0.40) CHRNB2CHRNA4CYP2D6CYP1A2HSD17B10
SCHEMBL28409392 0.75 PRCP (0.46) CYP2D6CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL9009806 0.74 HTR2A (0.40) CHRNB2CHRNA4DRD1DRD2DRD4
SCHEMBL28404711 0.73 PRCP (0.48) HSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117729945-A Fragrance composition, method of making and articles comprising the same 埃克苏德公司 2024-03-19 CN claimed
CN-114728968-A Condensed pyridone compound and preparation method and application thereof 上海济煜医药科技有限公司 2022-07-08 CN claimed
WO-2021052499-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海济煜医药科技有限公司 2021-03-25 WO claimed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US claimed
EP-1648886-B1 BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE LABOR DR (ES) 2009-12-09 EP claimed
US-7582720-B2 Transparent polycarbonate, poly(meth)acrylate core/shell particles; free of anthanthrones, anthraquinones, benzimidazoles, diketopyrrolopyrroles, isoindolinols, perinones, perylenes, phthalocyanines, quinacridones, quinophthalones which prevents degradation of polycarbonate; diffuser sheets BAYER MATERIAL SCIENCE AG (DE) 2009-09-01 US claimed
JP-2008531793-A 2008-08-14 JP claimed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US claimed
EP-1858979-A1 LIGHT-SCATTERING SHAPED ARTICLES OF HIGH LIGHT TRANSMISSION AND THE USE THEREOF IN FLAT SCREENS Bayer MaterialScience AG (DE) 2007-11-28 EP claimed
WO-2006094624-A1 LIGHT-SCATTERING SHAPED ARTICLES OF HIGH LIGHT TRANSMISSION AND THE USE THEREOF IN FLAT SCREENS BAYER MATERIALSCIENCE AG (DE) 2006-09-14 WO claimed
US-20060198999-A1 Transparent polycarbonate, poly(meth)acrylate core/shell particles; free of anthanthrones, anthraquinones, benzimidazoles, diketopyrrolopyrroles, isoindolinols, perinones, perylenes, phthalocyanines, quinacridones, quinophthalones which prevents degradation of polycarbonate; diffuser sheets BAYER MATERIALSCIENCE AG (DE) 2006-09-07 US claimed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP claimed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO claimed
EP-4366733-A1 TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF LANDOS BIOPHARMA, INC. (US) 2024-05-15 EP disclosed
EP-3927427-B1 LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME NIMMUNE BIOPHARMA INC (US) 2024-02-07 EP disclosed
CN-117500785-A Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases 细胞基因公司 2024-02-02 CN disclosed
EP-0135280-B1 NEW POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREBY COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1993-05-12 EP disclosed
US-4581429-A Polymerization process and polymers produced thereby COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 1986-04-08 US disclosed
EP-0135280-A2 New polymerization process and polymers produced thereby COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1985-03-27 EP disclosed
EP-0002792-A1 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them SANDOZ AG (CH) 1979-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 CHRNB2 1347/4885CHRNA4 1594/4885DRD1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.